• Director of the Antibody Drug Discovery Lab, an academic drug discovery program in the John P. and Kathrine G. McGovern Medical School at Houston
  • Director of the Texas Therapeutics Institute, a drug discovery program operated by the John P. and Kathrine G. McGovern Medical School at Houston
  • Professor of molecular medicine and holder of the Robert A. Welch Distinguished University Chair in Chemistry at UTHealth
  • Member of the faculty of The University of Texas Graduate School of Biomedical Sciences at Houston

Researchers in the laboratory of Zhiqiang An, Ph.D., are working on innovative treatments for cancer and other human diseases. In particular, they are developing targeted treatments involving the use of proteins called antibodies that can be engineered to latch onto tumor cells and disrupt their growth. These drugs are associated with fewer side effects. An’s research is supported by the Cancer Prevention & Research Institute of Texas, the National Institutes of Health and the pharmacy industry.  Prior to joining the faculty of the UTHealth Medical School, An served as an executive in the biotechnology and pharmaceutical industry. An received his Ph.D. degree from the University of Kentucky, Lexington, and his postdoctoral training at the University of Wisconsin-Madison.